Stephens Inc. AR increased its stake in GSK plc (NYSE:GSK – Get Rating) by 6.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,281 shares of the pharmaceutical company’s stock after purchasing an additional 2,291 shares during the period. Stephens Inc. AR’s holdings in GSK were worth $1,275,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of GSK. Pflug Koory LLC bought a new position in shares of GSK in the third quarter worth approximately $26,000. Northwest Investment Counselors LLC increased its position in shares of GSK by 339.0% in the fourth quarter. Northwest Investment Counselors LLC now owns 777 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 600 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new position in shares of GSK in the third quarter worth approximately $31,000. Janiczek Wealth Management LLC increased its position in shares of GSK by 49.8% in the fourth quarter. Janiczek Wealth Management LLC now owns 915 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 304 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after purchasing an additional 368 shares during the last quarter. 13.15% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have commented on GSK. Berenberg Bank increased their price target on shares of GSK from GBX 1,580 ($19.26) to GBX 1,730 ($21.08) in a research report on Friday, February 10th. TheStreet upgraded shares of GSK from a “c+” rating to a “b-” rating in a research report on Friday, December 30th. Morgan Stanley reduced their price target on shares of GSK from GBX 1,650 ($20.11) to GBX 1,535 ($18.71) in a research report on Wednesday, November 30th. Bank of America cut shares of GSK from a “neutral” rating to an “underperform” rating in a research report on Monday, December 5th. Finally, StockNews.com began coverage on shares of GSK in a research report on Thursday. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $1,576.88.
GSK Trading Up 0.7 %
GSK Cuts Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 13th. Investors of record on Friday, February 24th will be paid a $0.3404 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 4.00%. The ex-dividend date of this dividend is Thursday, February 23rd. GSK’s payout ratio is 15.50%.
GSK Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.
- Get a free copy of the StockNews.com research report on GSK (GSK)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Get Rating).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.